Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Title:
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Author:
Kantarjian, Hagop Thomas, Deborah Jorgensen, Jeffrey Jabbour, Elias Kebriaei, Partow Rytting, Michael York, Sergernne Ravandi, Farhad Kwari, Monica Faderl, Stefan Rios, Mary Beth Cortes, Jorge Fayad, Luis Tarnai, Robert Wang, Sa A Champlin, Richard Advani, Anjali O'Brien, Susan